|1.||Shigeto, Tatsuhiko: 2 articles (10/2007 - 04/2007)|
|2.||Yokoyama, Yoshihito: 2 articles (10/2007 - 04/2007)|
|3.||Mizunuma, Hideki: 2 articles (10/2007 - 04/2007)|
|4.||Xin, Bing: 2 articles (10/2007 - 04/2007)|
|5.||Rey, Rosario: 2 articles (12/2006 - 11/2004)|
|6.||Nader-Macías, María Elena: 2 articles (12/2006 - 11/2004)|
|7.||Valiathan, Manna: 1 article (01/2014)|
|8.||Gowdra, Vasantharaju S: 1 article (01/2014)|
|9.||Nampurath, Gopalan K: 1 article (01/2014)|
|10.||Nayak, Pawan G: 1 article (01/2014)|
|3.||Body Weight (Weight, Body)
10/01/2011 - "We administered racemic BOP (10 mg/kg body weight) to rats (CFA+) pre-administered clofibric acid (CFA, 280 mg/kg/day), and studied BOP, BOP-G, and BOP-T enantiomer concentrations in plasma and bile up to 12 h after administration. "
12/01/1999 - "Both pure enantiomers of fenvaleric acid were administered at 1.5 mmol/kg body weight/day; the clofibric acid at the same concentration was used as a positive control. "
02/01/1988 - "Body weight, kidney weight, and systemic blood pressure were not significantly altered by clofibric acid. "
07/01/1987 - "The long-term effects of clofibric acid (200 mg/kg body weight) injected subcutaneously from 6-36 weeks of age were assessed in obese, hyperlipemic Zucker rats. "
07/01/1978 - "Hypercholesterolaemic adult animals received 50, 100, 150 or 200 mg/kg body weight of either SRC-3605 or clofibrinic acid for 4 days. "
|4.||Ovarian Neoplasms (Ovarian Cancer)
04/01/2007 - "In this study, we investigated the inhibitory effect of clofibric acid (CA), a ligand for PPARalpha on growth of ovarian malignancy, in in vivo and in vitro experiments using OVCAR-3 and DISS cells derived from human ovarian cancer and aimed to elucidate the molecular mechanism of its antitumor effect. "
04/01/2007 - "Clofibric acid, a peroxisome proliferator-activated receptor alpha ligand, inhibits growth of human ovarian cancer."
10/01/2007 - "In this study, we investigated the inhibitory effect of clofibric acid (CA), a ligand for peroxisome proliferator-activated receptor (PPAR)alpha, and pioglitazone, a ligand for PPARgamma, on ovarian cancer in in vivo experiments using human ovarian cancer cell lines, and we aimed to elucidate the molecular mechanism of their anticancer effect. "
|5.||Hepatocellular Carcinoma (Hepatoma)
01/01/2013 - "In the human hepatoma cell line HepG2, retinoic acid, clofibric acid, and bile acid treatment can only modestly increase hepatitis B virus (HBV) biosynthesis. "
01/15/2002 - "Clofibric acid down-regulation of metallothionein IIA in HepG2 human hepatoma cells."
08/01/2001 - "Activation of the activator protein-1 by the peroxisome proliferator clofibric acid in rat H4IIEC3 hepatoma cells."
09/15/1999 - "Effects of the peroxisome proliferator clofibric acid on superoxide dismutase expression in the human HepG2 hepatoma cell line."
01/15/2002 - "As metallothionein proteins play an important antioxidant role, the aim of the present study was to investigate the expression of metallothionein IA (MTIA) and IIA (MTIIA) in HepG2 human hepatoma cells exposed to clofibric acid. "
|10.||Proteins (Proteins, Gene)
|2.||Phototherapy (Light Therapy)